Sebelipase Alfa News
Sebelipase Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Sebelipase Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
- Evidence level: L5
- Predicted indications (20):
- Scheie syndrome (99.8%)
- Hurler syndrome (99.8%)
- growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant (99.8%)
- cholesteryl ester storage disease (99.7%)
- Wolman disease with hypolipoproteinemia and acanthocytosis (99.7%)
- Gaucher disease (99.7%)
- lysosomal storage disease with skeletal involvement (99.6%)
- autosomal ichthyosis syndrome with fatal disease course (99.6%)
- Tay-Sachs disease (99.6%)
- Wolman disease (99.6%)
- benign neoplasm of adrenal gland (99.6%)
- adult Krabbe disease (99.5%)
- mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies (99.5%)
- Krabbe disease (99.4%)
- cholesterol metabolism disease (99.4%)
- lysosomal acid lipase deficiency (99.4%)
- metachromatic leukodystrophy (99.4%)
- encephalopathy due to prosaposin deficiency (99.4%)
- infantile neuronal ceroid lipofuscinosis (99.3%)
- alpha-mannosidosis (99.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.